Expired CME Article

Clinical Pathological Characteristics and Management of Acute Respiratory Distress Syndrome Resulting from Influenza A (H1N1) Virus

Authors: Samer Homsi, MD, Natasa Milojkovic, MD, Yamen Homsi, MD

Abstract

Young adults, especially pregnant woman and patients with pre-existing medical conditions, appear to be at risk for the development of severe acute respiratory distress syndrome (ARDS) from influenza A (H1N1) infection, leading to critical hypoxemia. This may require high ventilator settings, the use of nonconventional modes, and extracorporeal membrane oxygenation in some cases. This severe ARDS may be related to prolonged and virulent viral infection, inducing ongoing aberrant immune responses and leading to extensive lung damage. Duration of antiviral therapy, the timing of steroid introduction, and moving away from standard ventilation techniques in ARDS may be key points in disease management.


Key Points


* Acute respiratory distress syndrome (ARDS) from influenza A (H1N1) infection may cause critical hypoxemia, requiring high ventilator settings, the use of nonconventional modes, and in some cases, extracorporeal membrane oxygenation.


* Severe ARDS may be related to prolonged and virulent viral infection, inducing ongoing aberrant immune responses and leading to extensive lung damage.


* Clinicians should watch for signs of possible clinical deterioration, such as shortness of breath—especially in the high-risk group—and should seek early hospital referral.


* Duration of antiviral therapy, timing of introducing steroids, and moving away from standard ventilation techniques in ARDS may be key points in the management of this disease.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Centers for Disease Control and Prevention. 2009 H1N1 Early Outbreak and Disease Characteristics. Available at: http://www.cdc.gov/H1N1FLU/surveillanceqa.htm. Accessed October 27, 2009.
 
2. Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A (H1N1) virus infection-Michigan, June 2009. MMWR Morb Mortal Wkly Rep 2009;58:749–52. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5827a4.htm. Accessed July 17, 2009.
 
3. Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators; Davies A, Jones D, Bailey M, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA 2009;302:1888–1895.
 
4. Saleeby E, Chapman J, Morse J, et al. H1N1 Influenza in pregnancy: cause for concern. Obstet Gynecol 2009;114:885–891.
 
5. Van Wissen M, Keller TT, Ronkes B, et al. Influenza infection and risk of acute pulmonary embolism.Thromb J 2007;5:16.
 
6. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel human influenza A (H1N1) infection. Am J Respir Crit Care Med 2010;181:72–79.
 
7. Morens DM, Taubenberger JK, Fauci AS. Prominent role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198:962–970.
 
8. Ruest A, Michaud S, Deslandes S, et al. Comparison of the Directigen flu A+B test, the QuickVue influenza test, and clinical case definition to viral culture and reverse transcription-PCR for rapid diagnosis of influenza virus infection. J Clin Microbiol 2003;41:3487–3493.
 
9. Uyeki TM, Prasad R, Vukotich C, et al. Low sensitivity of rapid diagnostic test for influenza. Clin Infect Dis 2009;48:e89–e92.
 
10. Rello J, Rodríguez A, Ibañez P, et al; H1N1 SEMICYUC Working Group. Intensive care adult patients with severe respiratory failure caused by influenza A (H1N1)v in Spain. Crit Care 2009;13:R148.
 
11. Uyeki T. Diagnostic testing for 2009 pandemic influenza A (H1N1) virus infection in hospitalized patients. N Engl J Med 2009;361:e114.
 
12. Interim Recommendations for Clinical Use of Influenza Diagnostic Tests During the 2009–10 Influenza Season. Atlanta, Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/h1n1flu/guidance/diagnostic_tests.htm. Accessed November 24, 2009.
 
13. Ward P, Small I, Smith J, et al. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005;55 suppl:i5–i21.
 
14. Centers for Disease Control and Prevention. Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Virus Infection in Two Summer Campers Receiving Prophylaxis—North Carolina, 2009. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5835a1.htm. Accessed September 11, 2009.
 
15. Meduri GU, Golden E, Freire AX, et al. Methylprednisolone infusion in early severe ARDS: results of a randomized controlled trial. Chest 2007;131:954–963.
 
16. Steinberg KP, Hudson LD, Goodman RB, et al; National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 2006;354:1671–1684.
 
17. Quispe-Laime AM, Bracco JD, Barberio PA, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med2010:36:33–41.
 
18. Maclntyre N. Guidelines for Alternative Modes of Ventilation Used in the Management of Patients with ARDS Secondary to H1N1 Infection. American Thoracic Society. Available at: http://www.thoracic.org/clinical/critical-care/salvage-therapies-h1n1/pages/alternative-modes.php.
 
19. Luks AM. An Overview of Salvage Therapies for Acute Respiratory Distress Syndrome Caused By H1N1 Infection. American Thoracic Society. Available at: http://www.thoracic.org/clinical/critical-care/salvage-therapies-h1n1/pages/overview.php#prone.
 
20. Guerin C, Gaillard S, Lemasson S, et al. Effects of systematic prone positioning in hypoxemic acute respiratory failure: a randomized controlled trial. JAMA 2004;292:2379–2387.
 
21. Gattinoni L, Tognoni G, Pesenti A, et al; Prone-Supine Study Group. Effect of prone positioning on the survival of patients with acute respiratory failure. N Engl J Med 2001;345:568–573.
 
22. Zapol WM, Snider MT, Hill JD, et al. Extracorporeal membrane oxygenation in severe acute respiratory failure. A randomized prospective study. JAMA 1979;242:2193–2196.
 
23. Plotkin JS, Shah JB, Lofland GK, et al. Extracorporeal membrane oxygenation in the successful treatment of traumatic adult respiratory distress syndrome: case report and review. J Trauma 1994;37:127–130.
 
24. Morton A, Dalton H, Kochanek P, et al. Extracorporeal membrane oxygenation for pediatric respiratory failure: five-year experience at the University of Pittsburgh. Crit Care Med 1994;22:1659–1667.
 
25. Zwischenberger JB, Conrad SA, Alpard SK, et al. Percutaneous extracorporeal arteriovenous CO2 removal for severe respiratory failure. Ann Thorac Surg 1999;68:181–187.
 
26. Parcevaux M, Antok E, Boisson V, et al. Acute respiratory distress due to Influenza A (H1N1) S-OIV and extracorporeal oxygenation: the benefit of a multidisciplinary care network [in French]. Ann Fr Anesth Reanim 2010;29:145–148.
 
27. Freed DH, Henzler D, White CW, et al; Canadian Critical Care Trials Group. Extracorporeal lung support for patients who had severe respiratory failure secondary to influenza A (H1N1) 2009 infection in Canada. Can J Anaesth 2010;57:240–247.